Manufacturing of Citrated Plasma Control Reagent (Normal Level)

The contract requires the manufacture of a functionally stable, citrated human plasma control solution specifically designed for use in prothrombin time (PT) and activated partial thromboplastin time (APTT) coagulation assays. The product must meet stringent formulation consistency standards, ensuring reproducible performance across batches, and must be production-grade free from any biological or chemical contaminants that could interfere with assay accuracy. The solution must remain stable when stored under refrigerated conditions and maintain its functional integrity over its intended shelf life to support reliable clinical laboratory testing. Production must comply with all applicable quality and regulatory requirements for diagnostic reagents, with emphasis on traceability, process validation, and documentation of critical control points. The item is to be delivered to a U.S. military location identified as APO with a ZIP code of 09898, indicating service to U.S. defense medical facilities. The solicitation, issued under the NAICS code 325414 for biological product manufacturing, was posted on July 28, 2026, with proposals due by August 3, 2026, and is structured as a subcontract opportunity under the Department of Defense’s Medical Supply Chain organization, with no set-aside designation applied.